- Report
- March 2024
- 195 Pages
Global
From €3259EUR$3,374USD£2,789GBP
€3621EUR$3,749USD£3,099GBP
- Report
- March 2024
- 184 Pages
Global
From €3259EUR$3,374USD£2,789GBP
€3621EUR$3,749USD£3,099GBP
- Report
- February 2024
- 175 Pages
Global
From €4829EUR$5,000USD£4,132GBP
- Report
- April 2024
- 293 Pages
Global
From €5264EUR$5,450USD£4,504GBP
- Report
- October 2023
- 141 Pages
Global
From €2414EUR$2,499USD£2,065GBP
- Clinical Trials
- April 2024
- 230 Pages
Global
From €2897EUR$3,000USD£2,479GBP
- Report
- August 2023
- 500 Pages
Global
From €9175EUR$9,500USD£7,852GBP
- Report
- March 2024
- 200 Pages
Global
From €4008EUR$4,150USD£3,430GBP
- Clinical Trials
- April 2024
- 180 Pages
Global
From €2415EUR$2,500USD£2,066GBP
- Clinical Trials
- April 2024
- 180 Pages
Global
From €2897EUR$3,000USD£2,479GBP
- Drug Pipelines
- April 2024
- 40 Pages
Global
From €1207EUR$1,250USD£1,033GBP
- Report
- November 2023
- 47 Pages
Global
From €3858EUR$3,995USD£3,302GBP
- Report
- January 2022
- 200 Pages
Global
From €7244EUR$7,500USD£6,199GBP
- Report
- January 2022
- 200 Pages
Global
From €7244EUR$7,500USD£6,199GBP
- Report
- January 2022
- 200 Pages
Global
From €7244EUR$7,500USD£6,199GBP
- Report
- January 2022
- 200 Pages
Global
From €7244EUR$7,500USD£6,199GBP
- Report
- January 2022
- 60 Pages
Global
From €3815EUR$3,950USD£3,265GBP
- Report
- January 2022
- 60 Pages
Global
From €3815EUR$3,950USD£3,265GBP
- Report
- January 2022
- 60 Pages
Global
From €3815EUR$3,950USD£3,265GBP
- Report
- January 2022
- 60 Pages
Global
From €3815EUR$3,950USD£3,265GBP
Multiple Myeloma is a type of cancer that affects the plasma cells in the bone marrow. It is a form of Leukemia, and is the second most common type of blood cancer. Treatment for Multiple Myeloma typically involves a combination of chemotherapy, radiation therapy, and targeted drug therapy. The Multiple Myeloma drug market is composed of a variety of drugs, including proteasome inhibitors, immunomodulatory agents, monoclonal antibodies, and other targeted therapies. These drugs are used to treat the disease, as well as to reduce the risk of relapse.
The Multiple Myeloma drug market is highly competitive, with many companies offering a range of treatments. Some of the major players in the market include Bristol-Myers Squibb, Celgene, Novartis, Amgen, and Johnson & Johnson. Other companies such as Merck, Pfizer, and Takeda are also active in the market. Show Less Read more